IgA Nephropathy
Mohamed A. El-Shahawy, MD, MPH, MHA, FASN, CPI
Director and Principal Investigator
Clinical Professor of Medicine (Adjunct), Keck School of Medicine of USC
Protocol Overview
This Protocol will evaluate the efficacy of an investigational medication for adult patients with IGA Nephropathy, in addition to evidence-based standard-of-care medications aiming at reducing the proteinuria with the goal is to delaying the progression of kidney disease.
Key Inclusion Criteria
- Participant must be ≥ 18 years of age at the start of the protocol.
- Established diagnosis of primary IgAN based on kidney biopsy.
- Urine Protein Excretion: UPCR ≥ 0.75 g/g
- Kidney Function (eGFR): ≥ 30 mL/min/1.73 m²
Why join This clinical trial?
– Access to highly experienced Board certified Nephrologists
– Participation is voluntary, and you will learn all details about the protocol by Contacting with our clinical team contact us.
– Clinical trials offer additional care options for your condition, with access to new medicines at no cost.
– Help move science forward and improve human health, wellbeing, and quality of life.
– No cost to participate.
Compensation
- As a participant in this protocol, you will receive $75 after each visit.
- After each protocol visit for time spent completing the visit you will receive $75.00
- If you complete all required protocol visits, you will receive up to $2,250.
- Free Transportation will be provided.
Connect with Our Clinical Team
